Skip to main content

Table 5 Factors Associated with Persistence on DMD Therapy

From: Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study

Parameter

Hazard Ratio

Pr > ChiSq

Standard Error

Gender (reference: Male)

   

   Female

1.117

0.035

0.052

Age group (reference: Age 18-34)

   

   Age 35-44

0.701

<0.001

0.060

   Age 45-54

0.618

<0.001

0.061

   Age 55-64

0.672

<0.001

0.073

   Age 65+

0.847

0.274

0.152

Insurance plan type (reference: Comprehensive)

   

   HMO

1.305

0.001

0.079

   PPO

0.972

0.739

0.084

   POS

1.096

0.170

0.067

   POS with Capitation

1.002

0.984

0.109

Pre-index comorbidities

   

   Deyo-Charlson Comorbidity Index

1.049

0.045

0.024

   Depression

1.273

0.001

0.074

   Headache

1.162

0.008

0.056

   Neuropathic pain

0.844

0.003

0.058

   Urinary tract infection

1.206

0.010

0.072

Pre-index pharmacotherapy

   

   Antidepressant use

1.137

0.018

0.055

   Muscle relaxant use

1.175

0.005

0.057

  1. * This table was created using a Cox Model adjusting for time to DMD Therapy Gap of 31+ Days. The dependent variable was days to DMD therapy gap of 31+ days. Shown in this table are those factors of statistical significance. There were more parameters modeled in each category and others eliminated using backward selection.